Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 61225M102 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Montanova Capital, LLC
13G/A
Amendment 1
|
4.2% |
8/14/2026
Event 6/30/2026
|
|
| Montanova Capital, LLC | 4.2% | ||
| Averill Master Fund, Ltd. | 3.8% | ||
| Aaron Cowen | 4.2% | ||
|
Vestal Point Capital, LP
13G
|
5.4% |
8/14/2026
Event 6/30/2026
|
|
| Vestal Point Capital, LP | 5.4% | ||
| Ryan Wilder | 5.4% | ||
| Price T Rowe Associates Inc /MD/ 13G/A Amendment 7 | 10.5% |
7/8/2026
Event 6/30/2026
|
|
|
New Enterprise Associates 17, L.P.
13D/A
Amendment 4
|
7.9% |
7/6/2026
Event 7/1/2026
|
|
| New Enterprise Associates 17, L.P. | 7.9% | ||
| NEA Partners 17, L.P. | 7.9% | ||
| Nea 17 GP, LLC | 7.9% | ||
| Anthony A. Florence, Jr. | 7.9% | ||
| Mohamad H. Makhzoumi | 7.9% | ||
| Scott D. Sandell | 7.9% | ||
| Forest Baskett | 0% | ||
| Ali Behbahani | 0.2% | ||
| Carmen Chang | 0% | ||
| Edward T. Mathers | 0% | ||
| Paul Walker | 0% | ||
| Rick Yang | 0% | ||
|
TCG Crossover GP II, LLC
13G/A
Amendment 1
|
5.5% |
5/15/2026
Event 3/31/2026
|
|
| TCG Crossover GP II, LLC | 2.7% | ||
| TCG Crossover Fund II, L.P. | 2.7% | ||
| TCG Crossover GP III, LLC | 2.7% | ||
| TCG Crossover Fund III, L.P. | 2.7% | ||
| Chen Yu | 5.5% | ||
|
Baker Bros. Advisors LP
13G/A
Amendment 2
|
10.0% |
5/15/2026
Event 3/31/2026
|
|
| Baker Bros. Advisors LP | 10.0% | ||
| Baker Bros. Advisors (GP) LLC | 10.0% | ||
| Julian C. Baker | 10.0% | ||
| Felix J. Baker | 10.0% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 3
|
6.3% |
5/15/2026
Event 3/31/2026
|
|
| Biotechnology Value Fund L P | 3.4% | ||
| BVF I GP LLC | 3.4% | ||
| Biotechnology Value Fund II LP | 2.5% | ||
| BVF II GP LLC | 2.5% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 5.8% | ||
| BVF Partners L P/IL | 6.3% | ||
| BVF Inc/IL | 6.3% | ||
| Lampert Mark N | 6.3% | ||
|
Dimension Capital I, L.P.
13G/A
Amendment 2
|
8.1% |
4/22/2026
Event 3/31/2026
|
|
| Adam Goulburn | 8.1% | ||
| Zavain Dar | 8.1% | ||
| Nan Li | 8.1% | ||
| Dimension Management, L.P. | 8.1% | ||
| Dimension Capital I GP, LLC | 7.1% | ||
| Dimension Management GP, LLC | 8.1% | ||
| Dimension Capital I, L.P. | 7.1% | ||
| Dimension Capital II, L.P. | 1.1% | ||
| Dimension Capital II GP, LLC | 1.1% | ||
|
New Enterprise Associates 17, L.P.
13D/A
Amendment 3
|
9.7% |
3/19/2026
Event 3/17/2026
|
|
| New Enterprise Associates 17, L.P. | 9.6% | ||
| NEA Partners 17, L.P. | 9.6% | ||
| Nea 17 GP, LLC | 9.6% | ||
| Forest Baskett | 9.6% | ||
| Ali Behbahani | 9.7% | ||
| Carmen Chang | 9.6% | ||
| Anthony A. Florence, Jr. | 9.6% | ||
| Mohamad H. Makhzoumi | 9.6% | ||
| Edward T. Mathers | 9.6% | ||
| Scott D. Sandell | 9.6% | ||
| Paul Walker | 9.6% | ||
| Rick Yang | 9.6% | ||
|
Baker Bros. Advisors LP
13G/A
Amendment 1
|
6.7% |
2/17/2026
Event 12/31/2025
|
|
| Baker Bros. Advisors LP | 6.7% | ||
| Baker Bros. Advisors (GP) LLC | 6.7% | ||
| Julian C. Baker | 6.7% | ||
| Felix J. Baker | 6.7% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 2
|
5.9% |
2/17/2026
Event 12/31/2025
|
|
| Biotechnology Value Fund L P | 3.1% | ||
| BVF I GP LLC | 3.1% | ||
| Biotechnology Value Fund II LP | 2.3% | ||
| BVF II GP LLC | 2.3% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 5.4% | ||
| BVF Partners L P/IL | 5.9% | ||
| BVF Inc/IL | 5.9% | ||
| Lampert Mark N | 5.9% | ||
|
Dimension Capital I, L.P.
13G/A
Amendment 1
|
8.7% |
1/21/2026
Event 12/31/2025
|
|
| Adam Goulburn | 8.7% | ||
| Zavain Dar | 8.7% | ||
| Nan Li | 8.7% | ||
| Dimension Management, L.P. | 8.7% | ||
| Dimension Capital I GP, LLC | 8.7% | ||
| Dimension Management GP, LLC | 8.7% | ||
| Dimension Capital I, L.P. | 8.7% | ||
|
Versant Venture Capital VI, L.P.
13D/A
Amendment 6
|
3.4% |
1/9/2026
Event 1/7/2026
|
|
| Versant Venture Capital VI, L.P. | 3.4% | ||
| Versant Ventures VI GP, L.P. | 3.4% | ||
| Versant Ventures VI GP-GP, LLC | 3.4% | ||
| Versant Vantage I, L.P. | 1.6% | ||
| Versant Vantage I GP, L.P. | 1.6% | ||
| Versant Vantage I GP-GP, LLC | 1.6% | ||
|
Avoro Capital Advisors LLC
13G/A
Amendment 5
|
0% |
11/14/2025
Event 9/30/2025
|
|
| Avoro Capital Advisors LLC | 0% | ||
| Behzad Aghazadeh | 0% | ||
| Price T Rowe Associates Inc /MD/ 13G/A Amendment 6 | 7.5% |
11/14/2025
Event 9/30/2025
|
|
|
Versant Venture Capital VI, L.P.
13D/A
Amendment 5
|
5.1% |
11/12/2025
Event 11/10/2025
|
|
| Versant Venture Capital VI, L.P. | 5.1% | ||
| Versant Ventures VI GP, L.P. | 5.1% | ||
| Versant Ventures VI GP-GP, LLC | 5.1% | ||
| Versant Vantage I, L.P. | 2.4% | ||
| Versant Vantage I GP, L.P. | 2.4% | ||
| Versant Vantage I GP-GP, LLC | 2.4% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 4.8% |
10/31/2025
Event 9/30/2025
|
|
|
TCG Crossover GP II, LLC
13G
|
7.2% |
10/17/2025
Event 10/10/2025
|
|
| TCG Crossover GP II, LLC | 3.6% | ||
| TCG Crossover Fund II, L.P. | 3.6% | ||
| TCG Crossover GP III, LLC | 3.6% | ||
| TCG Crossover Fund III, L.P. | 3.6% | ||
| Chen Yu | 7.2% | ||
|
Dimension Capital I, L.P.
13G
|
7.7% |
10/3/2025
Event 5/16/2024
|
|
| Adam Goulburn | 7.7% | ||
| Zavain Dar | 7.7% | ||
| Nan Li | 7.7% | ||
| Dimension Management, L.P. | 7.7% | ||
| Dimension Capital I GP, LLC | 7.7% | ||
| Dimension Management GP, LLC | 7.7% | ||
| Dimension Capital I, L.P. | 7.7% | ||
|
Avoro Capital Advisors LLC
13G/A
Amendment 4
|
6.1% |
8/14/2025
Event 6/30/2025
|
|
| Avoro Capital Advisors LLC | 6.1% | ||
| Behzad Aghazadeh | 6.1% | ||
|
FMR LLC
13G/A
Amendment 5
|
2.8% |
6/6/2025
Event 5/30/2025
|
|
| FMR LLC | 2.8% | ||
| Abigail P. Johnson | 2.8% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 1
|
9.2% |
5/15/2025
Event 3/31/2025
|
|
| Biotechnology Value Fund L P | 4.7% | ||
| BVF I GP LLC | 4.7% | ||
| Biotechnology Value Fund II LP | 3.8% | ||
| BVF II GP LLC | 3.8% | ||
| Biotechnology Value Trading Fund OS LP | 0.5% | ||
| BVF Partners OS Ltd. | 0.5% | ||
| BVF GP Holdings LLC | 8.5% | ||
| BVF Partners L P/IL | 9.2% | ||
| BVF Inc/IL | 9.2% | ||
| Lampert Mark N | 9.2% | ||
|
Suvretta Capital Management, LLC
13G
|
5.5% |
4/16/2025
Event 4/9/2025
|
|
| Suvretta Capital Management, LLC | 5.5% | ||
| Averill Master Fund, Ltd. | 5.1% | ||
| Aaron Cowen | 5.5% | ||
|
Avoro Capital Advisors LLC
13G/A
Amendment 3
|
7.1% |
2/14/2025
Event 12/31/2024
|
|
| Avoro Capital Advisors LLC | 7.1% | ||
| Behzad Aghazadeh | 7.1% | ||
| BlackRock, Inc. 13G | 6.3% |
2/4/2025
Event 12/31/2024
|
|
|
Biotechnology Value Fund L P
13G
|
7.2% |
1/31/2025
Event 1/24/2025
|
|
| Biotechnology Value Fund L P | 3.7% | ||
| BVF I GP LLC | 3.7% | ||
| Biotechnology Value Fund II LP | 3.0% | ||
| BVF II GP LLC | 3.0% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 6.6% | ||
| BVF Partners L P/IL | 7.2% | ||
| BVF Inc/IL | 7.2% | ||
| Lampert Mark N | 7.2% | ||
| Vanguard Group Inc 13G | 5.1% |
1/30/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 3.51 k | $41.9 k |
| 2026 Q2 | 203 | 94.6 M | $2.31 B |
| 2026 Q1 | 198 | 87.0 M | $1.43 B |
| 2025 Q4 | 170 | 64.5 M | $1.01 B |
| 2025 Q3 | 137 | 60.1 M | $445 M |
| 2025 Q2 | 120 | 62.7 M | $283 M |
| 2025 Q1 | 111 | 59.5 M | $276 M |
| 2024 Q4 | 111 | 61.0 M | $423 M |
| 2024 Q3 | 86 | 49.8 M | $264 M |
| 2024 Q2 | 82 | 46.0 M | $172 M |
| 2024 Q1 | 76 | 40.0 M | $282 M |
| 2023 Q4 | 83 | 40.2 M | $227 M |
| 2023 Q3 | 76 | 42.0 M | $201 M |
| 2023 Q2 | 71 | 39.7 M | $272 M |
| 2023 Q1 | 72 | 39.8 M | $310 M |
| 2022 Q4 | 72 | 41.8 M | $318 M |
| 2022 Q3 | 72 | 40.4 M | $330 M |
| 2022 Q2 | 58 | 38.8 M | $375 M |
| 2022 Q1 | 54 | 40.0 M | $561 M |
| 2021 Q4 | 54 | 36.3 M | $742 M |
| 2021 Q3 | 57 | 34.9 M | $759 M |
| 2021 Q2 | 49 | 32.1 M | $705 M |